Abstract
Commercial efforts in structural genomics focus on providing to pharmaceutical customers information that relates to the suitability of specific proteins as drug targets and the informed selection and refinement of lead compounds generated by high-throughput screening and rational approaches. These efforts follow a variety of business models and are impacted by activities in the public domain, recent technological advances, and the changing intellectual property landscape.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Boggon, T.J., Shan, W.S., Santagata, S., Myers, S.C. & Shapiro, L. Science, 286, 2119–2125 (1999).
Shapiro, L. & Scherer, P.W. Curr. Biol. 8, 335–338 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dry, S., McCarthy, S. & Harris, T. Structural genomics in the biotechnology sector. Nat Struct Mol Biol 7 (Suppl 11), 946–949 (2000). https://doi.org/10.1038/80718
Issue Date:
DOI: https://doi.org/10.1038/80718
This article is cited by
-
A tour of structural genomics
Nature Reviews Genetics (2001)